Total amount raised
$748.1 Million
Latest funding date
11/01/2024
Location
Humacyte has successfully raised funds through 15 funding rounds, with the latest being a Post-IPO Debt round. The company has attracted 16 investors, including notable names like Avenue Capital Group and Fresenius Medical Care.
Keep reading to explore the intricacies of Humacyte's fundraising journey and the investors backing this innovative biotechnology platform.
What Is Humacyte?
Humacyte is a pioneering company in the field of bioengineering and regenerative medicine, focusing on the development and manufacture of bioengineered human tissues and organs. The company is located in Morrisville, North Carolina, and has an employee count ranging from 101 to 250.
Specializing in products for vascular diseases and the replacement of anatomical conduits, Humacyte is publicly traded under the ticker NASDAQ:HUMA. Their innovative platform aims to create universally implantable, off-the-shelf, and regenerative tissues, with FDA approval for their Symvess™ product for vascular trauma repair.
How Much Funding Has Humacyte Raised?
- Round Name: Series C
- Amount Raised: USD 74,999,980
- Date: March 2018
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To accelerate product development and expand clinical trials.
- Round Name: Corporate Round
- Amount Raised: USD 150,000,000
- Date: June 2018
- Lead Investors: Fresenius Medical Care
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To support strategic partnerships and enhance manufacturing capabilities.
- Round Name: Debt Financing
- Amount Raised: USD 50,000,000
- Date: April 2021
- Lead Investors: Silicon Valley Bank
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To fund ongoing research and development activities.
- Round Name: Post-IPO Equity
- Amount Raised: USD 175,000,000
- Date: August 2021
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To scale operations and expand market reach.
- Round Name: Post-IPO Equity
- Amount Raised: USD 40,200,000
- Date: February 2024
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To enhance product pipeline and support regulatory approvals.
- Round Name: Post-IPO Equity
- Amount Raised: USD 15,000,000
- Date: November 2024
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To fund clinical trials and expand research initiatives.
- Round Name: Post-IPO Equity
- Amount Raised: USD 50,000,000
- Date: March 2025
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To support commercialization efforts and market expansion.
- Round Name: Post-IPO Equity
- Amount Raised: USD 60,000,000
- Date: October 2025
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To enhance product development and regulatory compliance.
- Round Name: Post-IPO Debt
- Amount Raised: USD 77,500,000
- Date: December 2025
- Lead Investors: Avenue Capital Group
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To strengthen financial position and support long-term growth.
Total Amount Raised: USD 662,699,980. Current Valuation: Not publicly disclosed.
Key Investors
- Avenue Capital Group
- Details: Avenue Capital Group is a global investment firm focused on distressed and undervalued debt and equity opportunities. They have been a key investor in Humacyte, particularly in the Post-IPO Debt rounds.
- Investment Focus Areas: Distressed debt, undervalued equity, special situations.
- Notable Investments: Humacyte, Neiman Marcus, MGM Resorts International.
- Fresenius Medical Care
- Details: Fresenius Medical Care is a leading provider of products and services for individuals with renal diseases. They have invested significantly in Humacyte to support strategic partnerships and enhance manufacturing capabilities.
- Investment Focus Areas: Renal care, medical devices, healthcare services.
- Notable Investments: Humacyte, NxStage Medical, Renal Research Institute.
- Silicon Valley Bank
- Details: Silicon Valley Bank provides various financial services to startups and growth companies. They have participated in Humacyte's Debt Financing round to support ongoing research and development activities.
- Investment Focus Areas: Technology, life sciences, venture capital.
- Notable Investments: Humacyte, Pinterest, Shopify.
- California Institute for Regenerative Medicine
- Details: The California Institute for Regenerative Medicine (CIRM) is a state agency that funds stem cell research and regenerative medicine projects. They have provided grant funding to Humacyte to support their innovative research.
- Investment Focus Areas: Stem cell research, regenerative medicine, biotechnology.
- Notable Investments: Humacyte, ViaCyte, Asterias Biotherapeutics.
What's Next for Humacyte?
Humacyte stands at the forefront of regenerative medicine, with opportunities in clinical trials and product development, particularly with their Symvess™ acellular tissue-engineered vessel. The scope of these opportunities is vast, encompassing advanced organ systems and tissue constructs, aligning with current industry trends in bioengineering.
Future fundraising efforts are likely, given their active engagement with investors and the broad scope of their pipeline. These funds will be crucial for scaling operations and expanding market reach. However, challenges such as regulatory compliance, market adoption, and competition in the biotech space may pose hurdles along the way.
Use Clay to Get Funding Data
Sales professionals, leverage Clay’s platform to access comprehensive fundraising data on companies like Humacyte and gather other critical business insights. Sign up for free to start transforming your sales strategy today.
